探讨微小病变型肾病机制及治疗  

Pathogenesis and treatment of minimal change disease

作　　者：杨传雄 顾伟男(综述) 周竹(审校)[1] YANG Chuanxiong;GU Weinan;ZHOU Zhu(Department of Nephrology,First Affiliated Hospital of Kunming Medical University,Kunming Yunnan 650032,China)

机构地区：[1]昆明医科大学第一附属医院肾内科,云南昆明650032

出　　处：《云南医药》2024年第5期86-89,共4页Medicine and Pharmacy of Yunnan

基　　金：云南省慢性肾病临床医学研究中心项目(202102AA100060);云南省“兴滇英才支持计划”名医项目。

摘　　要：MCD是儿童及青少年原发肾病综合征中最常见病例类型,临床主要以大量蛋白尿、低蛋白血症、水肿及高脂血症为主,目前该疾病常规治疗或加用激素疗效及预后均良好,但仍存在复发及激素抵抗,为治疗创造了难题,随着人们对微小病变肾病的深入研究,对该疾病的发生、发展机制有了一定的认识,在临床上为药物治疗提供了相关的依据,该文就MCD发病机制研究进展及miR-499与微小病变型肾病的联系进行相关阐述。minimal change disease(MCD)is the most common type of primary nephrotic syndrome in children and adolescents.The main clinical manifestations are massive proteinuria,hypoproteinemia,edema and hyperlipidemia.At present,the conventional treatment or glucocorticoid treatment of MCD has a good effect and prognosis,but there is still recurrence and glucocorticoid resistance,creating difficulties for treatment.With the in-depth study of minimal change disease,people have a certain understanding of the occurrence and development mechanism of the disease,and provide relevant basis for drug therapy in clinical practice.This article reviews the research progress of the pathogenesis of MCD and the relationship between miR-499 and minimal change disease.

关 键 词：微小病变型肾病 机制 治疗 

分 类 号：R692[医药卫生—泌尿科学]